1
Clinical Trials associated with VLT-015An Open Non-comparative Clinical Trial of the Pharmacokinetics, Safety and Tolerability of VLT-015, Tablets, 100 mg (Valentech LLC) With Single and Multiple Use in Patients With Schizophrenia
15 stable patients diagnosed with schizophrenia take 100 mg of VLT-015 once a day, 200 mg of VLT-015 once a day and 200 mg of VLT-015 on two consecutive days with an interval of 24 hours between doses. PK parameters are measured, tolerability and safety of the product are evaluated.
Start Date01 Feb 2021 |
Sponsor / Collaborator- |
100 Clinical Results associated with VLT-015
100 Translational Medicine associated with VLT-015
100 Patents (Medical) associated with VLT-015
100 Deals associated with VLT-015